Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alfuzosin for Pediatric Hydronephrosis and Neurogenic Bladder (Alfahydro)
NCT00576823Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label trial of alfuzosin in hydronephrosis and neurogenic bladder, sponsored by Sanofi. Started Dec 2007; status: completed.
02
Drugs
alfuzosin
03
Conditions
hydronephrosisneurogenic bladder
Beyond the preview
Go deeper on NCT00576823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00576823.